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Abstract The expression of the cytochrome P4501AI gene, 
CYP1A1, is induced by e.g. 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) mainly by transcriptional mechanisms. The inducers 
mediate their effect upon binding and activation of the aryl hydro° 
carbon receptor (AHR) transcription-factor complex. Utilizing 
chimeric CYP1AIICAT constructs transient gene expression ex- 
periments indicate that the putative negative regulatory element 
(NRE) of CYP1A1 influence the relative TCDD induced CAT 
activity in HepG2 cells, whereas this effect was not observed in 
MCF-7 cells. Differences in the formation of cell-specific pro- 
tein-DNA complexes were demonstrated by gel retardation as- 
says suggesting a functional difference of NRE in these two cell 
lines. 
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1. Introduction 
The cytochrome P450 enzymes are a superfamily of isoen- 
zymes involved in the oxidative metabolism of a variety of 
endogenous compounds, including steroids, fatty acids, prosta- 
glandins, leukotrines and biogenic amines. Moreover, these 
enzymes play an important role in biotransformation f xenobi- 
otica [1,2], e.g. the metabolism of polycyclic aromatic hydrocar- 
bons (PAH) into their ultimate carcinogenic forms [3-5]. The 
P4501A family includes two genes, CYPIA1 and CYPIA2, and 
their expression is inducible by PAH and dioxins [2]. The most 
active form in the metabolism of PAH is the CYPIA1 gene 
product, exhibiting aryl hydrocarbon hydroxylase (AHH) ac- 
tivity [6,7]. In the human population a large variation in 
CYPIA1 inducibility has been observed [8-10]. Using human 
lymphoblast cultures approximately 10% were shown to exhibit 
a high AHH-inducibility to exposure of PAH, and this pheno- 
type was correlated to an increased risk of bronchogenic carci- 
noma [11]. Furthermore, moderate to high constitutive 
CYPIA1 expression has been shown to correlate with poor 
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prognosis in human breast cancer [12,13]. Studies have demon- 
strated that different human breast cancer cell lines vary greatly 
with respect o the basal and TCDD induced expression of 
CYP1A1 [14,15]. Interindividual differences in regulation of 
CYPIA1 seem to be related to differences in susceptibility o
carcinogens and it is therefore important o understand the 
cellular distribution and regulation of CYPIA1 contributing to 
activation of these compounds at the target site. 
The induction of this gene by e.g. 2,3,7,8,-tetrachloro- 
dibenzo-p-dioxin (TCDD) is regulated mainly at the transcrip- 
tional level via the aryl hydrocarbon receptor (AHR) [16,17]. 
As a ligand-activated transcription factor, the AHR activates 
the transcription of a large number of genes [2,18-20], of which 
CYP1A1 is the most extensively studied. The induction re- 
sponse is a complex sequence of events initiated by binding of 
the agonist o the AHR resulting in dissociation of 90-kDa heat 
shock protein, receptor activation/transformation, nuclear 
translocation and DNA-binding of the activated AHR complex 
to specific genomic sequences termed xenobiotic or dioxin re- 
sponsive lements (XREs, DREs). The activated nuclear AHR 
transcription factor complex is a heterodimer consisting of two 
basic region/helix-loop-helix proteins, the AHR and the AHR 
nuclear translocator (ARNT) protein [16,17,21]. Additional 
factors eem to be involved in tissue- and cell-specific modifica- 
tions of the induction response. These include the protein ki- 
nase-C dependent phosphorylation asan essential step for the 
DNA-binding activity of the AHR-transcription-complex 
[22,23], AHR level and CYPIA1 expression [24, 25]. Another 
cis-acting DNA element BTE (basic transcriptional e ement) 
located immediately upstream the transcription start site is 
required for maximal inducible xpression of the rat CYPIA1 
gene [26]. In vitro analyses of the mouse cyplal and the human 
CYP1A1 gene have indicated that the AHR-mediated activat- 
ing processes are regulated by negative regulatory mechanisms, 
and an autoregulatory effect of the endogenous mouse 
CYP1A1 protein has been suggested [17]. Deletion analyses of 
the human CYPIA1 promotor egion have indicated the pres- 
ence of a negative regulatory element (NRE) located between 
-833 and -558 bp [27]. This element is shown capable of down- 
regulating a heterologous promotor/enhancer involving spe- 
cific nuclear protein binding to a 21-bp palindrome (-794 to 
-774) [28]. 
The objective of this study was to investigate a possible cell 
specific effect(s) of the NRE on its natural promotor/enhancer 
(CYPIA1) activity in human hepatoma HepG2 and breast car- 
cinoma MCF-7 cells. The HepG2 cells were selected as proto- 
type for the study since CYP1A1 expression is highly inducible 
and previous NRE studies were carried out in this cell line [27]. 
MCF-7 was used as model for breast cancer cells. The effects 
of NRE on constitutive and TCDD induced activity of the 
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CYP1A1 promotor activity were analyzed by transient gene 
expression assays using chimeric CYP1Al - reporter  gene con- 
structs, and cell-specific DNA-binding activity of nuclear ex- 
tracts and analyzed by electrophoretic mobility shift assays 
(EMSA) using the 21-bp palindrome of NRE as probe. 
2. Materials and methods 
2.1. Materials, plasmids, and cells" 
All chemicals were obtained at the highest purity available from 
Sigma, Boehringer or Pharmacia. Restriction endonuclease and DNA 
modification enzymes were purchased from either New England Bio- 
labs or Life Technologies A/S, mammalian cell culture media, fetal calf 
serum and lipofectin from GIBCO BRL. 1-Deoxy[dichloroacetyl-1- 
14C]chloramphenicol (1-deoxy~4C-Cm) (55 Ci/mmol) in 0.25M Tris- 
HCI, pH 7.5, [0~-32p] and [7-32p]deoxyribonucleotide triphosphates, 
3,000 Ci and 5,000 Ci/mmol, respectively, were acquired from Amer- 
sham Corp., TCDD was obtained from Wellington Laboratories, 
Lenexa, Kansas, and oligonucleotides from DNA technology, Science 
Park, Aarhus, Denmark. The reporter plasmids used in this study are 
shown in Fig. 1. pRNHllc was provided by Dr. R.N. Hines, Detroit, 
MI. pdN1 lc was constructed by deletion of the proposed NRE (-833 
to -558) by digestion of pRNHllc with ApaI/SaclI enzymes, blunt- 
ending by T 4 DNA polymerase treatment and religation, pSdN1 lc was 
constructed by substitution of the NRE with the unrelated 275 bp 
BamH1/SalI fragment (Stuff'275) of the tet R gene in pBR327, pRSVflgal 
(encoding the fl-galactosidase enzyme) was kindly provided by Dr. R. 
Toftgaard, Karolinska Institute, Huddinge, Sweden. pC~0cat (carrying 
the BglII/EeoRI cat gene cartridge from pAlocat 2[29]) was kindly pro- 
vided by Dr. R.N. Hines, Detroit, MI, pSVOcat (derived from pSV2cat 
[30] by deletion of the SV40 early promotor/enhancer region) was pro- 
vided by Dr. P. Jorgensen, University of Aarhus, Denmark. pNRE10s, 
and pNRE~70 were constructed by use of the intact 275 bp NRE 
(NRE27s) fragment isolated after ApaIlSaeII digestion of the pRNH1 lc. 
The NRE275 was digested with BstNI, and the two NRE subfragments 
were isolated, blunt-ended using T4 DNA polymerase and cloned into 
the SmaI site ofpUC19. The plasmid constructs were verified by restric- 
tion endonuclease digestions and/or DNA sequence analysis [31]. The 
human hepatoblastoma cell line HepG2 (passage 76), purchased from 
American Type Culture Collection (Rockville, MD), was cultured in 
Dulbecco's Modified Eagle Medium (DMEM) with glutamax-1 supple- 
mented with 10% fetal bovine serum (FCS), 64 pg/ml garamycin R and 
incubated in a humidified incubator at 37°C, 5% CO2. The cells (pas- 
sage 77 87) were subcultured (1:6) every 3-4 days. The human breast 
carcinoma cell lines MCF-7 was obtained from the Breast Cancer Task 
Force Cell Culture Bank, Mason Research Institute (Worcester), used 
at passage 298-310, propagated in DMEM without Phenol red 
(DMEM-PH) supplemented with 1% FCS, 64 pg/ml garamycin R, 2.5 
mM glutamine, 6 pg/1 insulin, and incubated as described for HepG2. 
The cells were subcultured (1: 10) every 3-4 days, after trypsination 
DMEM-PH supplemented with 10% charcoal-stripped FCS was added 
for 24 h. 
2.2. Transient expression assays 
Transfections were done in triplicate in 60-mm-diameter dishes. The 
optimal DNA amount and ratio between reporter plasmid(s) and 
pRSVflgal (internal standard for transfection efficiency) were deter- 
mined by titration experiments. The HepG2 and MCF-7 cells followed 
different schedules. HepG2: (i) 5 x 105 HepG2 cells were plated 24 h 
before transfection with 6 ¢tg CYP1AI/cat reporter gene plasmid and 
0.6 pg pRSVflgal using 24 pg lipofectin in Opti-MEM Reduced Serum 
Medium; (ii) After 22 h the media was replaced with growth media 
containing 0.1% DMSO (solvent control) or 10 nM TCDD (induction); 
(iii) After another 26 h the cells were harvested. MCF-7: (i) 3.5 x 105 
cells plated in growth media containing 10% charcoal-stripped FCS; 
(ii) Media replacement (DMEM-PH, 1% FCS) 24 h later; (iii) Transfec- 
tion as described for HepG2 for 5 h followed by, (iv) treatment with 
DMSO (0.1%) or TCDD (10 riM) for 21 h and then the cells were 
harvested. Cell harvest and CAT assays were performed essentially as 
described [15] with following modifications. Cells were washed in ice- 
cold TNE (50 mM Tris-HC1, pH 7.6, 100 mM NaC1, 1 mM EDTA), 
and TNE + 5% glycerol was used for harvest and cell-extract prepara- 
tion. CAT activity was determined using 0.25/.tCi 1-deoxy~4C-Cm and 
1 mM acetyl coenzyme A as substrates. Cell extracts containing 10,ug 
protein was analyzed in parallel with control CAT (0.05 U; Pharmacia, 
Biotech). CAT activities were always measured in substrate xcess en- 
suring the reactions within the linear phase. After separation of 1- 
deoxy~4C-Cm and 3-acetyl, 1-deoxyt4C-Cm by thin-layer chromatogra- 
phy, the% acetylatedJ4C-Cm was quantitated by phosphorimage analy- 
ses (Molecular Dynamics, KEBO). The protein concentration was 
quantitated using Micro BCA Protein Assay Reagent (Pierce), and the 
fl-gal enzyme content was determined using an ELISA-fl-galactosidase 
kit (GIBCO BRL). CAT activity was normalized to transfection effi- 
ciency (fl-gal) and protein content. 
2.3. Electrophoretic mobility shift assay ( EMSA ) 
Nuclear extracts of HepG2 and MCF-7 were prepared as described 
in [32] after treatment of the cells with DMSO (0.1%) or TCDD (2 nM) 
in serum free growth media for 3 h. Protease inhibitors (2.5 pg/ml of 
antipain, aprotinin, leupeptin, and pepstatin and 0.2 mM phenyl-meth- 
ylsulfonyl fluoride) and 5 mM dithiothreitol (DTT) was added to all 
buffers. The nuclei were extracted in high salt buffer (0.4 M KC1) for 
45 min, and dialyzed for 12 h (0.1 M KCI). Protein concentration was 
determined by the Bradford dye-binding procedure (Bio-Rad). For 
EMSA, complementary oligonucleotides, carrying 5'EcoRIlYBamHI 
ends, corresponding to the 21-bp palindrome (-794 to -774, 5'- 
GTGCTCTGCCAATCAAAGCAC-3'), identified in NREt0s [28], 
were annealed (NREpa0 and labeled with [y-32p]ATP using T 4 polynu- 
cleotide kinase. Labeled probe was purified by Nick-Spin columns 
(Pharmacia). Unlabeled competing DNA included the NRE27s, the 
NRE~05 and NREtT0 fragments gel purified after digestion with EcoRII 
BamHI of their respective plasmids, or the unrelated BamHI/Sall 
StuffzTS fragment of pBR327. Gel retardation assays were performed 
essentially according to the instructions of the BandShift kit (Pharma- 
cia). Nuclear extract (10/tg of protein), 10 pg of poly(dl-dC), 10 pg 
acetylated BSA, and competing DNA were incubated for 5 min at room 
temperature (RT) in the presence of 10 mM Tris-HCl (pH 7.5), 50 mM 
NaC1, 0.5 mM DDT, 6.25 mM MgCI2, 0.05% NP40, and 1 mM EDTA, 
then radiolabeled probe (0.13 ng of DNA, lC~I 2,000 cpm) was added, 
and the reaction mixture (20 pl) was incubated for 20 min at RT before 
fractionation on a 5% polyacrylamide g l in low-ionic-strength buffer 
(7 mM Tris-HCl, pH 7.5, 3 mM sodium acetate, 1 mM EDTA) at 
constant current (200 V) with recirculation of running buffer and cool- 
ing. The gels were fixed (10% CHsCOOH, 2% glycerol and rinsed in 2% 
glycerol), dried at 80°C, visualized, and quantitated by phosphorimage 
analyses. 
3. Results and discussion 
The possible cell specific effects of NRE on basal as well as 
induced expression of C YP1A 1 were examined in human breast 
and hepatoma cells. Chimeric CYP1Al - reporter  gene plasmids 
were constructed and analyzed in transient gene expression 
assays. Deletion analyses of a gene promotor may cause posi- 
-1140 -833 -558 -49 +1 
Fig. 1. Structure of CYPIAllcat expression vectors. The parent plasmid 
pRNH1 lc: Contains -1140 to +2434 sequences of CYPIAI  including 
5'flanking sequences, exon 1 and intron 1 in front of the cat gene [27]. 
pdN1 lc: Deletion of the NRE fragment (-831 to -560) by digestion 
of pRNHllc with ApaIISacII enzymes, blunt-ending and religation. 
pSdNllc: Substitution of the NRE with an unrelated fragment 
(Stuf f275)  , the 275 bp BamHIISalI from the tet rt gene in pBR327. The 
position of the inserted Stuff27 sfragment is shown by dotted lines. 
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Fig. 2. Relative CAT activity and fold induction upon TCDD treatment in HepG2 (A) and MCF-7 (B) cells. Transfection and CAT assays were 
performed as described in section 2. The data were corrected for transfection efficiency (fl-gal), and normalized to the basal CAT activity of pRNH 11 c 
(DMSO), which was set to 1. Fold induction was obtained by the ratio of TCDD induced CAT activity over basal activity. *Significantly different 
from corresponding pRNH1 lc values, pClOcat and pSVOcat were used as control plasmids. Values given as mean + S.D., n = 3~,. 
tion effects and influence the transcription activity [33], and 
thus result in misinterpretation. Therefore, plasmids carrying 
DNA segments harboring intact 5' regulatory sequences 
(pRNHl lc)  were analyzed in parallel with constructs, where 
NRE was deleted (pdN11 c) or substituted with unrelated DNA 
sequences (pSdN1 lc) cloned upstream of the cat gene (Fig. 1). 
Promotor strength of these chimeric plasmids were analyzed by 
transfection i to MCF-7 and HepG2 cells using the pRSVflgal 
as an internal standard for transfection efficiency. The results 
in Fig. 2 show the relative CAT activity in HepG2 or MCF-7 
cells treated with DMSO (solvent control) or 10 nM TCDD 
upon parallel transfection of the plasmid pRNH1 lc, pdN1 lc, 
pSdN 1 lc, and the control plasmids pC~ocat and pSVOcat. The 
basal CAT activity of the parent plasmid pRNH1 lc was set to 
1 in both cell lines. In HepG2 (Fig. 2A) and MCF-7 cells (Fig. 
2B) deletion of the 275 bp NRE fragment (pdN1 lc) resulted in 
an almost 2-fold increase in the constitutive activity of the 
CYP1A1 promotor, whereas ubstitution of the NRE with an 
unrelated DNA fragment of same size (pSdN1 lc) resulted in 
a significant decrease of the constitutive CAT activity com- 
pared with pRNHl lc  (MCF-7:0.81 P < 0.05, and HepG2: 
0.45, P < 0.05). Treatment of cells with 10 nM TCDD caused 
an approximately 10-fold induction of the pRNH1 lc encoded 
CAT activity in both cells lines. The TCDD induced CAT 
activity upon deletion of NRE (pdN1 lc) was similar to that 
observed for pRNH 11 c, however, the fold-induced activity was 
approximately 65% compared to pRNH1 lc in both cell lines 
(Fig. 2). In HepG2, pSdNl lc  caused a significant 1.4- and 
2.1-fold (P = 0.03 and P = 0.02) higher inducibility than the 
induced parent plasmid or upon deletion of NRE alone, respec- 
tively (Fig. 2A). In contrast, in MCF-7 neither the induced 
CAT activity nor the fold-induction of pSdN1 lc were different 
from the parent plasmid (Fig. 2B). Consistent with the data in 
this study a 10-fold induction of the pRNHI lc CAT activity 
upon inducer treatment of HepG2 was previously reported [27]. 
However, an 8-fold increase in the constitutive activity and a 
5-fold reduction of the induced activity of the C YP1A 1 promo- 
tor were observed upon deletion of NRE [27]. This discrepancy 
concerning deletion of NRE between the previous reported 
results and this study is unclear, but may be explained by 
differences in transfection design or cell passage number. The 
findings in the present study indicate that deletion of the NRE 
fragment alone causes position effects modulating the basal 
activity of the intact promotor, possibly by favoring the interac- 
tion between upstream transcription factors and the basic tran- 
scription machinery as previously suggested [33]. The lower 
fold-induced activity of the pdN 11 c promotor may be explained 
by a disturbed stereospecific alignment of protein binding 
DNA-elements (e.g. XREs) on the DNA helix. A requirement 
for stereospecific positioning of enhancer elements for induci- 
ble transcription was reported for the human proenkephalin 
gene [34], between the SV40 enhancer and early promotor ele- 
ments [33], and between glucocorticoid receptor binding sites 
[35]. Moreover, analysis of the CYP1A1 enhancer in intact 
mouse hepatoma cells has suggested that nucleosome position- 
ing over the enhancer influence AHR-DRE interactions imply- 
ing a spacing dependence of DREs for maximal enhancer activ- 
ity [36]. In addition, substitution of NRE (pSdN1 lc) indicates 
that the NRE possess DNA sequences essential for maximal 
constitutive activity of CYP1A1 in both HepG2 and MCF-7 
cells. The increase in fold-induced CAT activity upon substitu- 
tion of NRE (pSdN1 lc) in HepG2 indicates that a negative 
regulative ffect is exerted by the NRE segment on TCDD 
induced CYP1A1 expression i  HepG2 cells, whereas it has no 
effect in MCF-7 cells. This different effect of NRE in HepG2 
and MCF-7 suggests that cell specific components may be in- 
volved. 
Specific binding of nuclear extract protein(s) of HepG2 to the 
intact NRE275 and the subfragments NRE~05 (-833 to -728) 
and NRE~v0 (-728 to -558) has been demonstrated, each of 
which exerting a negative regulatory activity on a simian virus 
40 (SV40) enhancer/herpes simplex virus thymidine kinase 
(HSV tk) promotor activity [28]. The nuclear protein(s) recog- 
nized similar sites on both NRE subfragments, however, a 
21-bp palindrome (-794 to -774) of NRE~05 was the most 
important sequence for protein binding and negative regulatory 
activity [28]. In the present study EMSA was used to explore 
whether differences in putative regulatory proteins binding to 
the 21-bp palindrome could explain the different role of NRE 
on induced CYP1A1 expression in HepG2 and MCF-7. Nu- 
clear extracts from the cells lines, treated with either DMSO 
or 2nM TCDD for 3 h, were incubated with the 32P-labeled, 
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Fig. 3. Specific binding of nuclear extract proteins of HepG2 (A, C, E) and MCF-7 (B, D, F) cells. - ,  represents 32p-NREpal probe alone; +, represents 
the presence of nuclear extract without competitor. The specific complexes are indicated with an arrow (I, II, III). In A and B lanes 2-6 and lanes 
12-16 are nuclear extracts from DMSO, and lanes 7 11 and lanes 17 21 from TCDD treated cells. In C and D lanes 2-6 and 12-15 are DMSO extracts, 
and lanes 7 11 and 16-19 TCDD extracts. In E and F lanes 2-6 are from DMSO and lanes 7 11 are from TCDD treated cells. Competing DNA 
was present at 20-, 40-, 80-, or 100-fold molar excess. All reactions were carried out using 10/~g nuclear protein, 0.13 ng of DNA (10-12,000 cpm)/20/4. 
Reactions were repeated at least twice to establish reproducibility. 
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double stranded oligonucleotide containing the 21-bp palin- 
drome (3zp-NREpaj). Specific DNA-binding factors are consti- 
tutively expressed at similar levels in both cell lines (arrows, Fig. 
3A F), and the expression isneither enhanced by TCDD treat- 
ment (compare .g. lane 2 vs. lane 7 in Fig. 3A,B) nor does 
TCDD seem to increase the affinity of DNA-binding activity 
specific for 32p-NREp,l in the cell lines (Fig. 3A,B lanes 2-11). 
The results suggest hat an additional specific protein (III) 
binds to the NREpa~ probe in MCF-7 cells compared to HepG2. 
Competition mobility shift analyses how the presence of two 
NREpal specific nuclear HepG2 proteins (Fig. 3A, I and II, 
lanes 2-11), whereas three specific DNA-binding proteins were 
identified in MCF-7 (Fig. 3B, I, II, and III, lanes 2-11). These 
factors are highly specific since 100-fold molar excess of unla- 
beled NREpa: competed approximately 90% for binding with 
the 32p-NREpa: in nuclear extract of both cell lines, while equiv- 
alent molar excess of the unrelated Stuff275 fragment did not 
(Fig. 3A,B lanes 12-21). The relative mobilities of the I and the 
II complex in the two cell lines appeared alike, suggesting that 
similar or identical proteins are involved in the binding to the 
NREpal probe. In accordance with the results of Boucher et al. 
[28] the DNA sequences of the intact NRE275 and the two NRE 
subfragments NRE~05 and NREIT0 had the capacity to compete 
the binding of proteins pecific for 32P-NREpal (Fig. 3C-F). All 
three NRE fragments competed for 32p-NREpal-protein com- 
plexes in both cell lines, however, as expected the NRE~05, 
which harbor the 21-bp NREpa: palindrome, competed more 
strongly for binding with the 32p-labeled NREpal probe (Fig. 
3C,D lanes 2-11). Examination of the competition studies with 
the three NRE DNA fragments imply that the NREj70 only 
carries sequences recognized by complex II (HepG2) or com- 
plex II and III (MCF-7) (Fig. 3C,D lanes 12-19), still, a similar 
competition pattern was observed when the intact NRE275 frag- 
ment was used (Fig. 3E,F) suggesting a less specific competition 
reaction with larger DNA fragments. Since EMSA analyses, 
using NREj05 or NRE~70 as labeled probe, did not imply addi- 
tional differences between the two cell lines in protein-binding 
to the NRE (results not shown) it is hypothesized that the 
protein complex III plays a role with respect o the impaired 
effect of NRE on TCDD induced CYPIA1 promotor activity 
in MCF-7 cells. Presently, the identity and role of proteins 
interacting with NREpa j are unknown. Possibly, distinct pro- 
tein(s) binding to the NRE plays a role in the basal activity of 
the promotor/enhancer, and upon TCDD treatment interaction 
of this protein(s) with other factor(s) may modulate its action. 
The protein complex III may be a modified version of either 
complex I or complex II causing a modulation of its function, 
i.e. the study of viral immediate arly (IE) proteins provides 
evidence that both positive and negative regulation may be 
controlled by the modification of factors that interact with the 
promotor and enhancer [37]. Moreover, different spliced forms 
of the Oct-2 transcription factor exert cell specific functions e.g. 
as an activator in B-lymphocytes or as a repressor in neuronal 
cells [38]. Since no XREs are identified in the human NRE, and 
treatment with TCDD does neither activate nor enhance NRE- 
binding proteins, the results do not support he proposed mod- 
els for negative regulation through inhibition of the AHR func- 
tion [3943]. Furthermore, the suggested autoregulatory effect 
of endogenous murine cyplal [17] exerts its effect in a NRE 
independent manner in the human system (manuscript in prep- 
aration). Together, these studies implies that either post-trans- 
lational modifications (e.g. phosphorylation), different splicing 
forms or protein-protein teractions of factors acting via the 
NRE may determine the cell-and tissue-specific action of this 
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element. Interestingly, recent published results demonstrated 
the binding of an additional specific DNA-protein complex to 
the NRE~05 in nuclear extract of rodent hepatoma cells com- 
pared with HepG2 extract. However, in contrast o the human 
cells, this element was unable to down-regulate SV40 enhancer/ 
HSV tk promotor activity in rodent hepatoma cells [44]. Taken 
together with the present observations, these data suggest hat 
an additional NRE-specific-binding complex could be related 
to intertissue as well as interspecies lack of NRE function. The 
results presented here emphasize the need for a careful exami- 
nation of the proteins binding to the NRE to establish a func- 
tional correlation between factor binding and repressing activ- 
ity. Identification of the DNA elements and transcription fac- 
tors which receive and mediate signals upon environmental 
xenobiotica exposure will increase the knowledge of these 
mechanisms and further the understanding of interindividual 
and intertissue susceptibility to xenobiotica exposure. 
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